Slide 1: FY 2020 results
FY 2020 results Conference call and webcast for investors and analysts 11 February 2021
Slide 2: Forward-looking statements
Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement: this document contains certain forward-looking statements wit
Slide 3: Forward-looking statements, proposed acquisition of Alexion
Forward-looking statements, proposed acquisition of Alexion Important additional information In connection with the proposed transaction, the Group intends to file a registration statement on Form F-4 with the SEC, which will include a document that serves as a prospectus of the Group and a proxy st
Slide 4: Speakers
Speakers Pascal Soriot Dave Fredrickson Ruud Dobber Mene Pangalos Executive Vice President, Executive Director and Executive Vice President, Executive Vice President, BioPharmaceuticals Chief Executive Officer Oncology Business Unit BioPharmaceuticals R&D Business Unit Marc Dunoyer Pam Cheng Leon Wa
Slide 5: Agenda
Agenda Overview Oncology BioPharmaceuticals, Emerging markets Finance Pipeline update, news flow Closing and Q&A 5
Slide 6: FY 2020: strong and resilient double-digit performance
FY 2020: strong and resilient double-digit performance Key highlights Total revenue up by 10%, continuing double-digit trajectory underpinned by focused R&D and SG&A investment Revenue growth: new medicines1 +33%. Oncology +24% and New CVRM2 +9%. Respiratory & Immunology stable and Emerging markets
Slide 7: Strong progress in the late-stage pipeline
Strong progress in the late-stage pipeline Important milestones since the last results update Medicine Indication (geography) Regulatory Tagrisso adjuvant NSCLC1 (EGFRm2) (US) approvals Imfinzi new Q4W3 dosing (US, EU) Lynparza ovarian cancer (1st line4, HRD+5) (PAOLA-1) (EU, JP) prostate cancer (2n
Slide 8: FY 2020: total revenue +10%
FY 2020: total revenue +10% New medicines continued to grow Significant revenue recovery including New medicines the an anticipated Lynparza sales milestone major contributor $m 1,200 22% 14% 18% 17% +$3.5bn 1,000 incremental revenue of the new Total revenue growth, per cent 11% 11% 10% medicines co
Slide 9: FY 2020: diversified and double-digit growth
FY 2020: diversified and double-digit growth Oncology, US, Emerging markets drove performance Growth across Growth across therapy areas geographies Q4 2020 growth ratio FY 2020 growth ratio Q4 2020 growth ratio FY 2020 growth ratio $m % % $m % % $m % % $m % % Total revenue 7,410 10 100 26,617 10 100
Slide 10: Accelerating the expansion into immunology
Accelerating the expansion into immunology Alexion: immune-mediated rare disease global leader Compelling scientific complementarity and synergy Combination of two science- and patient-centric organisations Further-sustained, industry-leading double-digit revenue growth Improved profitability and st
Slide 11: Agenda
Agenda Overview Oncology BioPharmaceuticals, Emerging markets Finance Pipeline update, news flow Closing and Q&A 11
Slide 12: Tagrisso and Imfinzi
Tagrisso and Imfinzi Global growth boosted by Europe and EMs Tagrisso: 36% growth to $4.3bn Imfinzi: 39% growth to $2.0bn 1 Approvals 674 (NSCLC5), 514 (ES-SCLC6) $m Approvals 5 (adjuvant), 87 (1st line) and 89 (2nd line) $m 1,200 • US +24% (36% of total) 600 • US +14% (58% of total) Growth despite
Slide 13: Lynparza
Lynparza The globally-leading PARP1 inhibitor $m Lynparza Approvals 78 (ovarian), 76 (breast), 55 Lynparza $m 49% sales growth to $1.8bn (pancreatic) and 49 (prostate cancer) collaboration revenue 600 1,000 • US +40% (49% of total) 500 1st-line OC2 growth supported 800 by new use in prostate cancer
Slide 14: Calquence and Enhertu
Calquence and Enhertu Calquence accelerated; Enhertu launch continued Calquence Enhertu $m Approvals: 51 (CLL1) and 23 countries (MCL2) $m Approvals: US, EU, Japan (mBC5); US, Japan (mGC6) 200 • Global $522m; US $511m 40 • Global $96m; US $93m $200m in-market US sales • US CLL by Daiichi Sankyo; no.
Slide 15: BioPharmaceuticals: New CVRM
BioPharmaceuticals: New CVRM Farxiga inflection point; strong progress Diabetes/HF: 9% growth driven by Farxiga, continued Brilinta: growth $m the fastest-growing SGLT21 in the fastest-growing T2D2 class3 $m impacted by COVID-19 1,000 • Farxiga +30% • Brilinta +2%: COVID-19 impact in all regions and
Slide 16: BioPharmaceuticals: Respiratory & Immunology
BioPharmaceuticals: Respiratory & Immunology Solid growth excluding the COVID-19 impact to Pulmicort Respiratory Encouraging growth everywhere $m stable1 except EMs; Pulmicort impact in China 2,000 • US +18% • EMs -18% Symbicort (+23%); market, volume Pulmicort ($798m, -33%) lower and price growth.
Slide 17: BioPharmaceuticals: new launch medicines
BioPharmaceuticals: new launch medicines Portfolio of new medicines across uses and markets Fasenra Breztri Lokelma roxadustat Severe asthma COPD $m Hyperkalaemia $m Anaemia in CKD • Europe $203m (+70%); • EMs $14m • Global $76m; US $57m • EMs $30m Japan $100m (+14%) Ongoing launch in China; US mark
Slide 18: Emerging markets
Emerging markets Diverse and solid growth Emerging markets +10% Performance driven by new medicines +59% $m EMs ex China +9%; China +11% (33% of total revenue; $1.1bn1 incrementally) 2,500 • Oncology +36%: Tagrisso ($1.2bn); March 2021 NRDL inclusion 2,000 New CVRM +31%: Forxiga (+55%); Brilinta (+4
Slide 19: Agenda
Agenda Overview Oncology BioPharmaceuticals, Emerging markets Finance Pipeline update, news flow Closing and Q&A 19
Slide 20: Reported profit and loss
Reported profit and loss FY 2020 change % total Q4 2020 change % total $m % revenue $m % revenue Total revenue 26,617 10 100 7,410 10 100 - product sales 25,890 11 97 7,011 11 95 - collaboration revenue 727 (11) 3 399 (4) 5 Gross margin 79.5% 0.5 pp4 78.2% 1.1 pp Operating expenses1 17,684 (2) 66 5,
Slide 21: Core profit and loss
Core profit and loss FY 2020 change % total Q4 2020 change % total $m % revenue $m % revenue Total revenue 26,617 10 100 7,410 10 100 - product sales 25,890 11 97 7,011 11 95 - collaboration revenue 727 (11) 3 399 (4) 5 Gross margin 80.0% 0.3 pp 78.6% 2.0 pp Operating expenses 15,633 6 59 4,654 8 63
Slide 22: Analysis: core operating profit and net debt
Analysis: core operating profit and net debt Increasing operating leverage and cash flow progress Core operating profit Net debt broadly stable reflecting $m Sources of profit continued to progress $bn continued improvement in EBITDA 2,250 2,000 0.3 1,750 3.6 8.3 1.2 1,500 1.0 11.9 12.1 2.9 0.4 1,25
Slide 23: Financial priorities
Financial priorities FY 2020 results underpinned the strategic journey Deleveraging/dividend growth Revenue growth • As cash flow improves, deleveraging and progressive dividend policy +10% • Unchanged priorities for capital growth in total allocation revenue in 2020 Operating leverage • 59% ratio o
Slide 24: 2021 guidance
2021 guidance Total revenue Core EPS increase by a low faster growth to teens percentage $4.75 to $5.00 Guidance is at CER. The guidance does not incorporate any revenue or profit impact from sales of COVID-19 Vaccine AstraZeneca. The Company intends to report these sales separately from the next qu
Slide 25: 2021 and beyond: the acquisition of Alexion
2021 and beyond: the acquisition of Alexion Accelerating the strategic and financial development • Compelling scientific complementarity and synergy • Increased immunology presence: complement system platform, currently applied in rare diseases • Pipeline boosted with 11 molecules across 20+ program
Slide 26: Agenda
Agenda Overview Oncology BioPharmaceuticals, Emerging markets Finance Pipeline update, news flow Closing and Q&A 26
Slide 27: Continuing response to COVID-19
Continuing response to COVID-19 Advancing vaccine, antibody, other options COVID-19 Vaccine AZD7442 long-acting Other COVID AstraZeneca antibody (LAAB) combo efforts continue • Late-stage trials recruited; >55k • PROVENT and STORMCHASER • Farxiga participants Phase III trial in pre- and post- DARE-1
Slide 28: Building new standard of care: Farxiga
Building new standard of care: Farxiga From T2D to HF and CKD DAPA-HF Phase III trial DAPA-CKD Phase III trial New and upcoming milestones • HFrEF1: 26% risk reduction in • First SGLT2 inhibitor with benefit • New DAPA-MI3 Phase III trial primary endpoint in patients with and without T2D achieved fi
Slide 29: Building new standard of care: anifrolumab
Building new standard of care: anifrolumab The first new medicine for lupus (SLE) in 10 years Potential first-in-class Pooled analysis of the TULIP Regulatory and treatment for lupus (SLE) trial programme at ACR 2020 clinical status • Early and sustained reduction in • Regulatory submissions US, EU,
Slide 30: BioPharmaceuticals: 'What's next'
BioPharmaceuticals: ‘What’s next’ Expanding pipeline, including immunology What’s next What’s now Phase I/II new medicines, selected Phase III new medicines MEDI3506 Now PIIb MEDI3506 Now PII in roxadustat PT027 (IL331 mAb2) ✓ (IL33 mAb) asthma✓ anaemia in CKD asthma DKD3 asthma, COPD, AD11, COVID-1
Slide 31: Building new standard of care: Tagrisso
Building new standard of care: Tagrisso Moving into earlier lines of NSCLC, reshaping the standard of care 2nd line (T790M1) 1st line (EGFRm) Adjuvant (EGFRm) AURA3 Phase III trial FLAURA Phase III trial ADAURA Phase III trial Tagrisso Platinum-pemetrexed PFS2 by Tagrisso Chemotherapy investigator (
Slide 32: Building new standard of care: Calquence
Building new standard of care: Calquence All data in CLL support a best-in-class potential Relapsed/refractory (R/R) Front line (FL) BTK inhibitor head-to-head ASCEND Phase III trial ELEVATE-TN Phase III trial ELEVATE-RR Phase III trial Sharman, ASH 2019 IRC-Assessed Progression-Free Survival Median
Slide 33: Oncology: 'What's next'
Oncology: ‘What’s next’ Solid pipeline moving forward What’s next What’s now Phase III new medicines Now PIII Now PIII Phase I/II new medicines, selected datopotamab deruxtecan lung cancer ✓ camizestrant (AZD9833) breast cancer ✓ monalizumab capivasertib head & neck cancer breast, prostate cancer ad
Slide 34: Late-stage pipeline events in the 2021-2022 timeframe
Late-stage pipeline events in the 2021-2022 timeframe Busy news flow continues; Phase III readouts increase into 2021 H1 2021 H2 2021 2022 Regulatory Tagrisso - adjuvant NSCLC (EGFRm) (CN) Tagrisso - adjuvant NSCLC (EGFRm) (EU) Imfinzi - ES-SCLC (CN) Lynparza - breast cancer (BRCAm) (CN) Lynparza -
Slide 35: Agenda
Agenda Overview Oncology BioPharmaceuticals, Emerging markets Finance Pipeline update, news flow Closing and Q&A 35
Slide 36: AstraZeneca in summary
AstraZeneca in summary Pipeline-driven transformation Global presence Strong pipeline Improving financials Balanced specialty and 22 Phase III medicines and Eight blockbuster medicines primary-care franchises1 significant lifecycle projects Returned to durable Leading emerging markets Advancing earl
Slide 37: Questions & Answers
Questions & Answers Now launched: AIR As part of ongoing efforts to make sustainability data transparent and accessible, the new Analyst Interactive Reporting (AIR) centre provides sustainability data in a single platform, covering global information from key performance indicators for Access to hea
Slide 38: Appendix: 'What's next'
Appendix: ‘What’s next’ Next key milestone by project Oncology BioPharmaceuticals: CVRM Project Target Phase Indication Next milestone Project Target Phase Indication Next milestone GLP-1/ NASH Phase IIb data H2 2021 adavosertib WEE1 II uterine, ovarian cancer Phase III start cotadutide II glucagon
Slide 39: Use of AstraZeneca conference call, webcast and presentation slides
Use of AstraZeneca conference call, webcast and presentation slides The AstraZeneca webcast, conference call and presentation slides (together the ‘AstraZeneca materials’) are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make availabl